Allessandra Quevedo discusses the heightened levels of risk exposure spanning across the entire technological infrastructure connected to the pharmaceutical industry, from research and manufacturing, and from distribution and hospitals. Companies in the pharmaceutical industry contain increasingly growing (and massive) bodies of sensitive data, including proprietary information related to products as well as consumer healthcare information. Therefore, it is imperative that companies adapt systems and processes to making sure their proprietary and sensitive data remains secure and accessible from emerging cybersecurity threats.